Navigation Links
Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
Date:2/24/2009

an anticipated patient enrollment, drug manufacturing challenges, changing standards of care, clinical trial design, clinical outcomes, or delay or failure in obtaining regulatory approval in one or more important markets; (iii) the company's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or intellectual property licenses from third parties may be required in the future; and (iv) the outcome of any future intellectual property or other litigation related to the company's proprietary product candidates or complex commercial agreements. Other important risks and uncertainties are detailed in the company's reports and other filings with the Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K. Actual results could differ materially from the forward-looking statements contained in this press release. The company undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.

     Jennifer Ruddock, 650-631-4954
     Nektar Therapeutics

     Susan Noonan, 212-966-3650
     SAN Group



                             NEKTAR THERAPEUTICS
                    CONSOLIDATED STATEMENTS OF OPERATIONS
                 (In thousands, except per share information)
                                 (unaudited)

                                       Three-Months Ended  Twelve-Months Ended
                                           December 31,       December 31,
                                          2008     2007      2008      2007
    Revenue:
       Product sales and royalties       $12,400  $26,702   $41,255  $180,755
       Collaboration and other            15,952   39,071    48,930    92,272
    Total revenue                         28,352   65,773    90,185   273,027

    Operating costs and expenses:
 
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
2. Nektar Announces Retirement of Irwin Lerner from Board of Directors
3. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Nektar Therapeutics to Webcast R&D Day on November 12th
6. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
7. Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Second Quarter of 2008 on Wednesday, August 6, 2008, After Close of U.S.-Based Financial Markets
10. Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit
11. Nektars PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 21, 2015 Cambridge Semantics, the leading provider ... announced that 2014 was a record-breaking year across the board ... the Anzo Smart Data Platform and our Smart Data solutions, ... from diverse data which led to record growth for the ...
(Date:1/22/2015)... California (PRWEB) January 22, 2015 Pipette.com ... Offer to their comprehensive portfolio of Eppendorf products. ... customers to purchase a Centrifuge 5424/5424 R and receive ... of either Eppendorf Research plus or Eppendorf Reference 2 ...
(Date:1/22/2015)... Geneva, Switzerland (PRWEB) January 22, 2015 ... for characterized mammalian Research Cell Banks (RCBs) used for ... generated Research Cell Banks will include Next-Generation Sequencing ... cell’s genetic architecture de-risks biologic manufacturing by ensuring the ...
(Date:1/22/2015)... Jan. 22. 2015  Varian Medical Systems (NYSE: VAR ... honored for its commitment to sustainability with inclusion on a ... the highest ranked healthcare equipment company among the Corporate Knights ... World Economic Forum at Davos, Switzerland . ...
Breaking Biology Technology:Cambridge Semantics Announces Record Results for 2014 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2
... one of the largest provider of integrated and customized ... and investors that, on April 10, 2008, the National ... 264,000 m3 of,biodiesel, for delivery between July 1 and ... ensure supply of the necessary volumes for the,mandatory blend ...
... LAUSANNE, Switzerland, April 11 Galderma Pharma ... dermatology, today,announced that its U.S. holding company, ... CollaGenex Pharmaceuticals, Inc. (Nasdaq:,CGPI). As a result ... wholly owned,subsidiary of Galderma Laboratories., "We ...
... international start-up, CEOs, business development executives, and service providers ... ... the globe, MASSAPEQUA, N.Y. and CLEVELAND, April ... BioEnterprise Corporation, the Cleveland-based bioscience business,formation, recruitment, and acceleration initiative, ...
Cached Biology Technology:Galderma Completes Acquisition of CollaGenex 2Galderma Completes Acquisition of CollaGenex 3Galderma Completes Acquisition of CollaGenex 4IBF Conferences Inc*International Business Forum and BioEnterprise Corporation present the 2nd Annual Global Healthcare Investing Conference 2IBF Conferences Inc*International Business Forum and BioEnterprise Corporation present the 2nd Annual Global Healthcare Investing Conference 3
(Date:1/22/2015)...   EyeLock, Inc. , a market leader of iris-based identity ... to the new role of Senior Vice President of ... of mobile platforms and wearable solutions for EyeLock,s technologies. Gerber ... the semiconductor industry to his role at EyeLock, with expertise ...
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, ... to eliminate the pain of trying to remember their usernames ... biometrics fused to their smartphones. To assist people who have ... the company that created 1U and focuses on redefining identity, ...
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ) ... Global Watermarking and Fingerprinting Markets" report to ... This insight provides an overview ... markets. Watermarking aims to control and monitor piracy ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3The Global Watermarking and Fingerprinting Markets 2
... HONOLULU April 25, 2012 -- Many shark populations have ... excessive harvesting for their fins, as an incidental catch ... is particularly true for oceanic species. However, until now, a ... of Pacific reef sharks at a large geographic scale. ...
... disease normally found in subarctic climates has been identified for ... south as Herefordshire., Sclerotinia subarctica , a fungus known ... found in carrots and meadow buttercups in Perthshire by plant ... Life Sciences at the University of Warwick. , It is ...
... research sailboat gliding over glassy seas in the Pacific ... was littered with confetti-size pieces of plastic debris, until ... the particles disappeared. After taking samples of ... Proskurowski, a researcher at the University of Washington, discovered ...
Cached Biology News:Scientists provide first large-scale estimate of reef shark losses in the Pacific Ocean 2Wind pushes plastics deeper into oceans, driving trash estimates up 2Wind pushes plastics deeper into oceans, driving trash estimates up 3
... Reagent Grade C 19 H 9 Br ... PRODUCT SPECIFICATIONS Form: Powder Clarity of Solution: ... 3.0 - Yellow pH 4.6 - ... in agarose and acrylamide gel electrophoresis. Used ...
tracking dye in electrophoresis; free acid, C 19 H 10 BrO 5 S; MW: 669.96...
Denhardt's Solution is a mixture of blocking agents used in membrane-based hybridization protocols. The solution contains 1% Ficoll (type 400) 1% polyvinylpyrrolidone and 1% bovine serum albumin. Ste...
... ELF 97 Cytological Labeling Kit provides a ... detection of cellular targets, including cell-surface receptors ... Labeling Kit contains the patented ELF 97 ... yellow-green precipitate at the site of enzymatic ...
Biology Products: